Schonfeld Strategic Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-137	Closed	-$36K	–	2934
2022 Q3	$36K	Sell	137 -159	-54%	-$60.6K	﹤0.01%	2676
2022 Q2	$131K	Buy	296 +196	+196%	+$139K	﹤0.01%	2066
2022 Q1	$123K	Buy	+100	New	+$136K	﹤0.01%	2170
2021 Q3	–	Sell	-39	Closed	-$413K	–	2410
2021 Q2	$413K	Buy	+39	New	+$327K	﹤0.01%	1286
2020 Q4	–	Sell	-140	Closed	-$1.4M	–	1825
2020 Q3	$1.4M	Buy	140 +72	+106%	+$655K	0.03%	614
2020 Q2	$631K	Buy	+68	New	+$623K	0.02%	731
2019 Q3	–	Sell	-58	Closed	-$489K	–	1196
2019 Q2	$489K	Buy	+58	New	+$347K	0.02%	635

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Schonfeld Strategic Advisors's IRLA Position: Q4 2022 in Review

Schonfeld Strategic Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2022, closing a stake of 137 shares — an estimated $36K sold.

Schonfeld Strategic Advisors first reported a position in IRLA in Q2 2019 and held it in 7 quarters. The position peaked at $1.4M in Q3 2020. 48 funds tracked by Wall St. Rank hold IRLA as of Q4 2022.

Schonfeld Strategic Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Schonfeld Strategic Advisors sold 137 IRulya Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $36K.
Schonfeld Strategic Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
Schonfeld Strategic Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $1.4M in Q3 2020.
48 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.